Business Context and Reporting Period
Company: Revelation Biosciences, Inc. (REVB)
Filing Type: Form 8-K (Current Report)
Date of Report: August 9, 2024
Reporting Period: This filing announces financial results for the three and six months ended June 30, 2024. The company is an emerging growth company incorporated in Delaware.
Key Financial Metrics
The provided 8-K filing text serves as a notification of results and does not contain specific numerical data for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being detailed in the press release furnished as Exhibit 99.1, which is not included in the source text.
Material Changes
The filing text does not provide specific details regarding material changes versus prior comparable periods. It only indicates that results for the periods ended June 30, 2024, have been issued.
Guidance, Outlook, and Risks
Management Commentary: The filing references a press release (Exhibit 99.1) containing the full announcement of results but does not include the text of that commentary.
Legal Disclaimer: The information in Item 2.02 and Exhibit 99.1 is not treated as "filed" under Section 18 of the Exchange Act and will not be incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated August 9, 2024) for specific revenue, net loss, and cash position figures.
- Verify the company's cash runway and burn rate, as these are critical for pre-revenue biotechnology firms.
- Check for any updates on clinical trial progress or regulatory milestones mentioned in the full press release.
- Confirm the status of the redeemable warrants (REVBW) and any potential dilution impacts.